GemPharmatech, a Chinese firm that provides gene-modified mouse models and related services, has secured over 400 million yuan ($58.5 million) in a Series B round of financing led by GL Ventures, the venture capital unit of Asia-focused private equity major Hillhouse Capital Group.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
